In a press release on November 20, Conseco Announces Reinsurance Transaction

CARMEL, Ind., Nov 20, 2009 Conseco, Inc. (NYSE: CNO) today announced a new agreement under which its Bankers Life and Casualty Company subsidiary ("Bankers Life") will coinsure, with an effective date of October 1, 2009, about 237,000 life insurance policies with Wilton Reassurance Company ("Wilton Re"). Wilton Re will pay a ceding commission of approximately $45 million and 50% coinsure these policies, which will continue to be administered by Bankers Life.

About Conseco

Conseco, Inc.'s insurance companies help protect working American families and seniors from financial adversity: Medicare supplement, long-term care, cancer, critical illness and accident policies protect people against major unplanned expenses; annuities and life insurance products help people plan for their financial futures. For more information, visit Conseco's website at www.conseco.com.

-- November 20, 2009 NRG Energy (NYSE: NRG) trading at $23.55 on a volume of 791,637 shares

In a press release on November 20, NRG Energy, Inc. Announces Partial Redemption of 4.0% Convertible Preferred Stock

PRINCETON, N.J., Nov 20, 2009 NRG Energy (NYSE: NRG) announced today that it has called for redemption 210,000 of the 419,587 outstanding shares of its 4.0% Convertible Preferred Stock, representing approximately 50% of the total number of outstanding shares of preferred stock. The preferred stock redemption date will be December 21, 2009, and the redemption price will be $20.00 per share of preferred stock. The dividend payment due on December 15, 2009, on the preferred stock will be made in the usual manner.

About NRG Energy, Inc.

NRG Energy, Inc., a Fortune 500 company, owns and operates one of the country's largest and most diverse power generation portfolios. Headquartered in Princeton, NJ, the Company's power plants provide more than 24,000 megawatts of generation capacity--enough to supply more than 20 million homes. NRG's retail business, Reliant Energy, serves more than 1.6 million residential, business, commercial and industrial customers in Texas. A past recipient of the energy industry's highest honors--Platts Industry Leadership and Energy Company of the Year awards, NRG is a member of the U.S. Climate Action Partnership (USCAP), a group of business and environmental organizations calling for mandatory legislation to reduce greenhouse gas emissions. More information is available atwww.nrgenergy.com.

-- November 20, 2009 Northrop Grumman Corporation (NYSE:NOC) trading at $54.66 on a volume of 582,624 shares.

In a press release out on November 20, U.S. Air Force Awards $302.9 Million Production Contract to Northrop Grumman for Five Global Hawk High-Altitude, Long-Endurance Unmanned Aircraft Systems

SAN DIEGO, Nov 20, 2009 The U.S. Air Force has awarded Northrop Grumman Corporation (NYSE:NOC) a $302.9 million fixed price incentive fee contract for five RQ-4 Global Hawk high-altitude, long-endurance (HALE) unmanned aircraft systems (UAS). Under the Lot 7 production contract, the company will build two Block 30 systems and three Block 40 systems for the 303d Aeronautical Systems Group at Wright Patterson AFB in Dayton, Ohio.

The award also includes a ground station consisting of a launch and recovery element and a mission control element, plus two additional sensor suites that will be retrofitted into previous production aircraft. The contract runs through 2011.

About Northrop Grumman Corporation

Northrop Grumman Corporation is a leading global security company whose 120,000 employees provide innovative systems, products, and solutions in aerospace, electronics, information systems, shipbuilding and technical services to government and commercial customers worldwide.

-- November 20, 2009 Pfizer Inc. (NYSE: PFE) last at $18.42 a volume of 26.35M shares

In a press release out on November 20,FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Revatio is the Only Treatment in Its Class with Both Oral and Intravenous Formulations

NEW YORK, Nov 20, 2009 Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio(R) (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.

Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Revatio was added to background epoprostenol therapy. The efficacy of Revatio has not been adequately evaluated in patients taking bosentan concurrently. Revatio Injection is for the continued treatment of patients with pulmonary arterial hypertension who are currently prescribed Revatio Tablets but who are temporarily unable to take oral medication.

About Pfizer Inc.

Pfizer Inc. (NYSE: PFE) is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. In June 2008, Pfizer completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals, Inc. through a merger of Pfizer's wholly owned subsidiary, Explorer Acquisition Corp., with and into Encysive. In June 2008, it also completed the acquisition of Serenex, Inc., a biotechnology company with a Heat Shock Protein 90 development portfolio. In July 2009, Pfizer bought back a 29.52% stake in its Indian arm, Pfizer Limited, increasing its stake to 70.75%.In October 2009, Pfizer Inc. acquired Wyeth.

-- November 20, 2009 Aegean Marine Petroleum Network Inc. (NYSE: ANW) last at $26.75 on a volume of 40,517 shares

In a press release out on November 20, Aegean Marine Petroleum Network Inc. Awarded Stand-By Oil Spill Recovery Services Contract by European Maritime Safety Agency

PIRAEUS, Greece, Nov 20, 2009 Aegean Marine Petroleum Network Inc. (NYSE: ANW) today announced its Belgian subsidiary, Aegean Bunkers at Sea N.V., has been awarded a contract by the European Maritime Safety Agency (EMSA) to increase the available oil pollution response capacity in the English Channel and its Atlantic approaches.

About Aegean Marine Petroleum Network Inc.

Aegean Marine Petroleum Network Inc. is an international marine fuel logistics company that markets and physically supplies refined marine fuel and lubricants to ships in port and at sea. The Company procures product from various sources (such as refineries, oil producers, and traders) and resells it to a diverse group of customers across all major commercial shipping sectors and leading cruise lines. Currently, Aegean has a global presence in 14 markets, including Vancouver, Montreal, Mexico, Jamaica, Trinidad and Tobago, West Africa, Gibraltar, U.K., Northern Europe, Piraeus, Patras, the United Arab Emirates, Singapore as well as Tangiers, Morocco.

-- November 20, 2009 Boston Scientific Corporation (NYSE: BSX) trading at $8.12 on a volume of 3.68M shares

In a press release out on November 20, Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent

Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets

NATICK, Mass. and LONDON, Nov 20, 2009 Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex(R) Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com

www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

CONTACT: PicksThatMove e-mail: Info@picksthatmove.com WWW: http://www.picksthatmove.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

"The FDA approval of Geodon provides an additional treatment option for patients with bipolar disorder, who require maintenance therapy to keep the symptoms of the disease under control," said Charles Bowden, clinical professor of psychiatry and pharmacology, University of Texas Health Science Center.

The efficacy and safety of Geodon for the adjunctive maintenance treatment of bipolar disorder were studied in a six-month, double-blind, randomized, placebo-controlled trial in adult patients with bipolar I disorder. After an open-label stabilization period of 10 to 16 weeks, 240 patients were randomized to continue on Geodon plus lithium or valproate, or to have Geodon replaced by placebo.(4) The primary endpoint in this study was time to recurrence of a mood episode requiring intervention.

The data demonstrated that Geodon plus lithium or valproate was superior to placebo plus lithium or valproate in increasing the time to recurrence of a mood episode. During six months of treatment, 19.7 percent of patients in the Geodon arm required intervention for a mood episode, compared with 32.4 percent of patients in the placebo arm.(4)

The adjunctive Geodon treatment regimen was generally well-tolerated.(4) Discontinuation due to adverse events occurred in 13 percent of patients in the placebo group, compared with 9 percent of those in the Geodon group.(5) The safety and tolerability data from this study are consistent with Geodon's already well-established safety profile in adult patients.

"The recurrence of mood episodes associated with bipolar disorder can have a devastating impact on patients' lives," said Dr. Ilise Lombardo, senior medical director, Pfizer Specialty Care. "This approval underscores Pfizer's commitment to supporting people suffering from serious mental health disorders."

Geodon is also FDA-approved for the treatment of acute manic and mixed episodes associated with bipolar disorder, with or without psychotic features, and for the treatment of schizophrenia. Since the FDA approval of Geodon in February 2001, nearly 2 million adult patients have been treated with this important therapy.(6)

Important Safety Information

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Geodon is not approved for the treatment of elderly patients with dementia-related psychosis.

Geodon is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs. Geodon has a greater capacity to prolong the QTc interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first.

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with Geodon. NMS can cause hyperprexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.

Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with Geodon, and it is not known if Geodon is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

In short-term schizophrenia trials, the most commonly observed adverse events associated with Geodon at an incidence of greater-than or equal to 5% and at least twice the rate of placebo were somnolence and respiratory tract infection.

The most common adverse events associated with Geodon in adult patients with bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision.

Please visit www.GEODON.com for full prescribing and patient information.

Pfizer Inc.: Working together for a healthier world(TM)

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

(1) National Institute of Mental Health. Bipolar disorder. Available at: http://www.nimh.nih.gov/health/publications/bipolar-disorder/nimhbipolar.pdf. Accessed October 27, 2009.

(2) Solomon DA, Keitner GI, Miller IW, Shea MT, Keller MB. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry. 1995;56:5-13.

(3) Sajatovic M. Bipolar disorder: disease burden. Am J Manag Care. 2005;11:S80-S84.

(4) Vieta E, Bowden C, Ice KS, et al. A 6-month, randomized, placebo-controlled, double-blind trial of ziprasidone plus a mood stabilizer in subjects with bipolar I disorder. Poster presented at the 17th European Psychiatric Association European Congress of Psychiatry, January 25, 2009, Lisbon, Portugal.

(5) Pfizer Inc. Clinical study report synopsis: Protocol A1281137. A phase 3, randomized, 6-month, double blind trial in subjects with bipolar I disorder to evaluate the continued safety and maintenance of effect of ziprasidone plus a mood stabilizer (vs placebo plus a mood stabilizer) following a minimum of 2 months of response to open-label treatment with both agents.

(6) Data on file. Pfizer Inc.

SOURCE: Pfizer Inc.

Pfizer 
Media: 
Gwen Fisher, 484-865-5160 
or 
Investors: 
Jennifer M. Davis, 212-733-0717

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html